Targeting c-FLIP appears to be a highly promising therapeutic strategy to reduce the apoptotic threshold because its overexpression can protect cancer cells from both TRAIL and chemotherapy-induced apoptosis, while small interfering RNA- (siRNA-) mediated downregulation of c-FLIP is able to sensitize cancer cells to FASL, TRAIL, and chemotherapeutic agents [39, 101]. The gene discussed is FASLG; the disease is cancer.